Abstract: The present invention relates to a Fab-scFv fusion protein specifically binding to (i) an antigen being expressed on the surface of a tumor cell or an autoreactive immune cell via the Fab scaffold, and (ii) an antigen being expressed on the surface of a leukocyte, preferably cytotoxic lymphocyte via the scFv fragment

Abstract: The present invention relates to a molecule having binding specificities for (a) CD123; (b) CD16 and (c) CD33. The present invention further relates to the molecule of the invention, wherein the molecule comprises a first immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD123; a second immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD16; and a third immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD33. The present invention furthermore relates to a nucleic acid molecule encoding the molecule of the invention. In addition, the present invention relates to diagnostic and pharmaceutical compositions and the use of the molecule or the nucleic acid molecule of the invention in the treatment of acute myeloid leukaemia and/or myelodysplastic syndrome.

Abstract: The present invention relates to a nucleic acid molecule encoding a polypeptide, wherein the polypeptide comprises (a) a first immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to an antigen expressed on tumour cells; (b) a second immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to an antigen expressed on tumour cells; and (c) a third immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to an effector cell antigen, wherein the effector cell is selected from the group consisting of NK cells, T cells, neutrophilic granulocytes, monocytes and macrophages; wherein at least one of the antigens expressed on tumour cells and bound by the immunoglobulin domain of (a) or (b) is an antigen expressed on tumour stem cells and/or on tumour precursor or progenitor cells; and wherein the ratio of immunoglobulin domai

Abstract: PTT staple fibers which are characterised by a novel combination of properties. In combination with novel stress-strain properties and modulus parameters, staple fibers or textiles or home textiles having extremely desirable aesthetics and service quality are obtained. Economical two-stage process for the production of PTT staple fibers. The melt spinning is carried out at a high polymer throughput and a spinning take-off speed of at least 600 m/min. In a separate fiber drawing frame, the stretching, heat-setting, crimping and drying are carried out.